Assessing risk of lymph node invasion in complete responders to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Rocco Simone FlammiaGabriele TudertiEugenio BolognaAntonio MinoreFlavia ProiettiLeslie Claire LicariRiccardo MastroianniUmberto AnceschiAldo BrassettiAlfredo BoveLeonardo MisuracaSimone D'AnnunzioMaria Consiglia FerrieroSalvatore GuaglianoneGiuseppe ChiacchioCosimo De NunzioCostantino LeonardoGiuseppe SimonePublished in: BJU international (2024)
Based on these findings, we postulate that PLND could potentially be omitted in patients exhibiting CR after NAC, due to negligible risk of LNI. Prospective Phase II trials are needed to explore this challenging hypothesis.
Keyphrases
- neoadjuvant chemotherapy
- lymph node
- phase ii
- end stage renal disease
- muscle invasive bladder cancer
- clinical trial
- sentinel lymph node
- locally advanced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- open label
- transcription factor
- peritoneal dialysis
- patient reported outcomes
- squamous cell carcinoma
- randomized controlled trial
- study protocol